Mice harboring CJ cell xenografts (B-cell lymphoma cells) that were injected with 20 mg/kg of L-Bcl-2 biweekly for five weeks displayed delayed disease progression and had an 80% survival rate. Here, BCL2 is linked to B-cell non-Hodgkin lymphoma.